NCT06726265 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06726265
Title	Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Acronym	TACTI-004
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Immutep S.A.S.
Indications	lung non-small cell carcinoma
Therapies	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Paclitaxel + Pembrolizumab Cisplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	TUR \| ROU \| POL \| LVA \| LTU \| ITA \| IRL \| HUN \| HRV \| GRC \| GBR \| ESP \| DEU \| CAN \| BGR \| BEL \| AUT \| AUS

Additional content available in CKB BOOST